-

07:00:42 AM

PRLD Stock News

PRLD - Prelude Therapeutics Inc

03/15/23 8:30 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged

RHEA-AI

positive

03/15/23 8:00 AM

Nasdaq : PRLD

clinical triallow float

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in

RHEA-AI

neutral

03/01/23 8:30 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On March 16,

RHEA-AI

neutral

02/09/23 9:05 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February 14, at 8:40

RHEA-AI

neutral

11/14/22 8:00 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0

RHEA-AI

neutral

10/18/22 8:00 AM

Nasdaq : PRLD

low float

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. On Monday,

RHEA-AI

neutral

08/09/22 8:00 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the second half of 2022

RHEA-AI

neutral

05/10/22 8:00 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022

RHEA-AI

positive

03/16/22 7:30 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Reports Full Year 2021 Financial Results

Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and

RHEA-AI

positive

PRLD Data

IndustryPharmaceutical Preparation Manufacturing
Websitepreludetx.com
Security namePrelude Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees116
Tags
- Health Technology
- Biotechnology

About Prelude Therapeutics Inc

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.